Key Laboratory of Organofluorine Chemistry, Shanghai Institute of Organic Chemistry, University of Chinese Academy of Sciences, Chinese Academy of Sciences, 345 Lingling Road, Shanghai 200032, P. R. China.
Acc Chem Res. 2021 Jul 20;54(14):2946-2958. doi: 10.1021/acs.accounts.1c00252. Epub 2021 Jun 29.
Recently, the strategic installation of a fluorine atom or a fluoroalkyl group site-selectively at the specific position of the target molecule has become a routine approach and daily practice for medicinal chemists in their endeavor to fine tune the structure of the lead compound to improve its physicochemical properties such as the cell membrane permeability and metabolic stability. Among many fluoroalkyl groups, the difluoromethylthio group (-SCFH) has attracted recent intense attention. Largely due to the weak acidity of the proton in the difluoromethylthio group, the difluoromethylthio group is generally considered to be a lipophilic hydrogen-bonding donor and a bioisostere of the hydroxy/thio group that might interact with the heteroatom of the enzyme via a hydrogen bond to improve the binding selectivity of the drug molecule. Besides, the difluoromethylthio group is less lipophilic, less electron-withdrawing, and less stable to the acidic or basic environment than its analogue trifluoromethylthio group (-SCF), making it easier to regulate the metabolic stability of drug molecules. These beneficial effects render the difluoromethylthio group one of the most favorable functional groups in drug design; consequently, there is an urgent need to develop new strategies for the efficient introduction of the difluoromethylthio group into small molecules under mild conditions. Over the last few decades, several different approaches to the preparation of difluoromethylthiolated compounds have been developed, including the difluoromethylation of thiolated substrates with an electrophilic/nucleophilic difluoromethylating reagent or the insertion of a difluoromethyl carbene into the S-H bond of the thiols. In contrast, we adopt an alternative approach to the preparation of difluoromethylthiolated compounds by late-stage direct difluoromethylthiolation of the specific substrates with a difluoromethylthiolating reagent. With this aim in mind, in the last 6 years we have successfully developed a toolbox of reagents that are capable of the direct introduction of the difluoromethylthio group into the target molecules, including nucleophilic difluoromethylthiolating reagent [(SIPr)AgSCFH] , electrophilic difluoromethylthiolating reagent PhthSCFH , three optically pure difluoromethylthiolating reagents camphorsultam-SCFH , radical difluoromethylthiolating reagent PhSOSCFH , and reagent PhSOSCFClH that could be used for the preparation of F-labeled [F]ArSCFH. These reagents reacted with a broad range of substrates to get access to difluoromethylthiolated compounds efficiently, thus providing medicinal chemists a powerful weapon for the direct introduction of the difluoromethylthio group into promising molecules during the search for new drugs.
最近,在目标分子的特定位置上选择性地进行氟原子或全氟烷基基团的战略安装,已经成为药物化学家们调整先导化合物结构以改善其物理化学性质(如细胞膜通透性和代谢稳定性)的常规方法和日常实践。在许多全氟烷基基团中,二氟甲基硫基(-SCFH)最近引起了强烈关注。主要由于二氟甲基硫基中质子的弱酸性,二氟甲基硫基通常被认为是亲脂性氢键供体和羟基/硫基的生物等排体,它可能通过氢键与酶的杂原子相互作用,从而提高药物分子的结合选择性。此外,与类似物三氟甲基硫基(-SCF)相比,二氟甲基硫基的脂溶性更小、电子受主性更小、对酸性或碱性环境的稳定性更小,因此更容易调节药物分子的代谢稳定性。这些有益的效果使得二氟甲基硫基成为药物设计中最有利的官能团之一;因此,迫切需要开发在温和条件下有效引入二氟甲基硫基的新策略。在过去的几十年中,已经开发出几种制备二氟甲基硫代化合物的不同方法,包括使用亲电/亲核二氟甲基化试剂对硫醇化底物进行二氟甲基化,或通过二氟甲基卡宾插入硫醇的 S-H 键。相比之下,我们采用了一种替代方法,通过使用二氟甲基硫代试剂对特定底物进行后期直接二氟甲基硫代化来制备二氟甲基硫代化合物。基于此目的,在过去的 6 年中,我们成功开发了一套试剂工具箱,这些试剂能够将二氟甲基硫基直接引入目标分子中,包括亲核二氟甲基硫代试剂[(SIPr)AgSCFH]、亲电二氟甲基硫代试剂 PhthSCFH、三种光学纯二氟甲基硫代试剂樟脑磺酰胺-SCFH、自由基二氟甲基硫代试剂 PhSOSCFH 和试剂 PhSOSCFClH,可用于制备 F 标记的[F]ArSCFH。这些试剂与广泛的底物反应,有效地得到二氟甲基硫代化合物,从而为药物化学家提供了一种强大的武器,用于在寻找新药时直接将二氟甲基硫基引入有前途的分子中。